Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.

Bin Bin Wu, Kam Tong Leung, Ellen Ngar-Yun Poon

International journal of molecular sciences 2022 Feb 09

filter terms:

Anthracyclines, such as doxorubicin, are effective chemotherapeutic agents for the treatment of cancer, but their clinical use is associated with severe and potentially life-threatening cardiotoxicity. Despite decades of research, treatment options remain limited. The mitochondria is commonly considered to be the main target of doxorubicin and mitochondrial dysfunction is the hallmark of doxorubicin-induced cardiotoxicity. Here, we review the pathogenic mechanisms of doxorubicin-induced cardiotoxicity and present an update on cardioprotective strategies for this disorder. Specifically, we focus on strategies that can protect the mitochondria and cover different therapeutic modalities encompassing small molecules, post-transcriptional regulators, and mitochondrial transfer. We also discuss the shortcomings of existing models of doxorubicin-induced cardiotoxicity and explore advances in the use of human pluripotent stem cell derived cardiomyocytes as a platform to facilitate the identification of novel treatments against this disorder.

Citation

Bin Bin Wu, Kam Tong Leung, Ellen Ngar-Yun Poon. Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity. International journal of molecular sciences. 2022 Feb 09;23(3)